Literature DB >> 17015690

The peroxisome proliferator-activated receptor gamma (PPARgamma) ligands 15-deoxy-Delta12,14-prostaglandin J2 and ciglitazone induce human B lymphocyte and B cell lymphoma apoptosis by PPARgamma-independent mechanisms.

Denise M Ray1, Filiz Akbiyik, Richard P Phipps.   

Abstract

Peroxisome proliferator-activated receptor gamma (PPARgamma) is a transcription factor important for adipogenesis and more recently has been shown to be an anticancer target. PPARgamma ligands, including the endogenous ligand 15-deoxy-Delta12,14-PGJ2 (15d-PGJ2) and synthetic ligands like ciglitazone and troglitazone, all induce apoptosis in normal and malignant human B lymphocytes, but the dependency of PPARgamma for apoptosis induction is unknown. In this study, we used a PPARgamma dominant-negative approach and a small molecule irreversible PPARgamma antagonist and found that these inhibitors prevented PPARgamma activation but did not prevent B cell apoptosis induced by 15d-PGJ2 or ciglitazone. In addition, a PPARgamma agonist that is a structural analog of 15d-PGJ2, and lacks the electrophilic carbon of the 15d-PGJ2 cyclopentenone ring, activated PPARgamma but did not kill B lymphocytes, further supporting a non-PPARgamma-mediated mechanism. To further investigate the apoptotic mechanism, the effects of 15d-PGJ2 and ciglitazone on reactive oxygen species were investigated. 15d-PGJ2, but not ciglitazone, potently induced reactive oxygen species in B lymphocytes, implicating the reactive nature of the 15d-PGJ2 structure in the apoptosis mechanism. In addition, 15d-PGJ2 caused an almost complete depletion of intracellular glutathione. Moreover, incubation with glutathione reduced ethyl ester, an antioxidant, prevented apoptosis induced by 15d-PGJ2, but not by ciglitazone. These findings indicate that the expression of PPARgamma may not be predictive of whether a normal or malignant B lineage cell is sensitive to PPARgamma agonists. Furthermore, these new findings support continued investigation into the use of PPARgamma agonists as agents to attenuate normal B cell responses and as anti-B cell lymphoma agents.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17015690     DOI: 10.4049/jimmunol.177.8.5068

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  38 in total

1.  Albumin-binding and tumor vasculature determine the antitumor effect of 15-deoxy-Delta-(12,14)-prostaglandin-J(2) in vivo.

Authors:  Jai Prakash; Ruchi Bansal; Eduard Post; Alie de Jager-Krikken; Marjolijn N Lub-de Hooge; Klaas Poelstra
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

2.  15-deoxy-Delta12,14 prostaglandin J2-induced heme oxygenase-1 in megakaryocytes regulates thrombopoiesis.

Authors:  J J O'Brien; C J Baglole; T M Garcia-Bates; N Blumberg; C W Francis; R P Phipps
Journal:  J Thromb Haemost       Date:  2008-10-10       Impact factor: 5.824

3.  Combined bezafibrate and medroxyprogesterone acetate: potential novel therapy for acute myeloid leukaemia.

Authors:  Farhat L Khanim; Rachel E Hayden; Jane Birtwistle; Alessia Lodi; Stefano Tiziani; Nicholas J Davies; Jon P Ride; Mark R Viant; Ulrich L Gunther; Joanne C Mountford; Heinrich Schrewe; Richard M Green; Jim A Murray; Mark T Drayson; Chris M Bunce
Journal:  PLoS One       Date:  2009-12-07       Impact factor: 3.240

4.  Anticancer Role of PPARgamma Agonists in Hematological Malignancies Found in the Vasculature, Marrow, and Eyes.

Authors:  P J Simpson-Haidaris; S J Pollock; S Ramon; N Guo; C F Woeller; S E Feldon; R P Phipps
Journal:  PPAR Res       Date:  2010-02-28       Impact factor: 4.964

5.  Electrophilic peroxisome proliferator-activated receptor-gamma ligands have potent antifibrotic effects in human lung fibroblasts.

Authors:  Heather E Ferguson; Ajit Kulkarni; Geniece M Lehmann; Tatiana M Garcia-Bates; Thomas H Thatcher; Krystel R Huxlin; Richard P Phipps; Patricia J Sime
Journal:  Am J Respir Cell Mol Biol       Date:  2009-03-13       Impact factor: 6.914

6.  Peroxisome proliferator-activated receptor gamma overexpression suppresses growth and induces apoptosis in human multiple myeloma cells.

Authors:  Tatiana M Garcia-Bates; Steven H Bernstein; Richard P Phipps
Journal:  Clin Cancer Res       Date:  2008-10-15       Impact factor: 12.531

7.  Antitumor activity of a novel series of alpha-aryloxy-alpha-methylhydrocinnamic acid derivatives as PPAR gamma agonists against a panel of human cancer cell lines.

Authors:  Xishan Xiong; Yangliang Ye; Lili Fu; Bing Dai; Jieqiong Liu; Jieshuang Jia; Jing Tang; Lin Li; Li Wang; Jianhua Shen; Changlin Mei
Journal:  Invest New Drugs       Date:  2008-08-13       Impact factor: 3.850

8.  Pyrimidinyl-arylpropionic acid derivatives: viable resources in the development of new antineoplastic agents.

Authors:  Xishan Xiong; Li Wang; Yangliang Ye; Lili Fu; Minli Chen; Qingyi Wang; Moyan Liu; Jing Tang; Bing Dai; Jianhua Shen; Changlin Mei
Journal:  Invest New Drugs       Date:  2009-06-17       Impact factor: 3.850

9.  A novel role for MAP1 LC3 in nonautophagic cytoplasmic vacuolation death of cancer cells.

Authors:  R Kar; P K Singha; M A Venkatachalam; P Saikumar
Journal:  Oncogene       Date:  2009-05-18       Impact factor: 9.867

10.  Effects of 15-deoxy-delta12,14-prostaglandin J2 (15d-PGJ2) and rosiglitazone on human gammadelta2 T cells.

Authors:  Haishan Li; C David Pauza
Journal:  PLoS One       Date:  2009-11-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.